TNF and rheumatoid arthritis: According to a case-control study which investigated the frequency of COVID-19 incidence in 254 eligible patients with rheumatoid arthritis (RA) or seronegative spondyloarthropathies (SpA), TNF-α blockers including adalimumab, infliximab, and etanercept decreased significantly the risk of developing COVID-19 in patients with RA and SpA.